此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ONC-PluReceptor NK细胞联合Epcoritamab和Tafasitamab治疗复发或难治性B细胞非霍奇金淋巴瘤患者的I/II期临床试验

2026年10月31日 更新者:M.D. Anderson Cancer Center

ONC-PluReceptor NK细胞联合埃普可利他单抗和他法西他单抗治疗复发性或难治性B细胞非霍奇金淋巴瘤患者的I/II期临床试验

The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or refractory B-cell Non-Hodgkin Lymphoma. The safety of this treatment will also be studied.

研究概览

详细说明

Primary Objective:

To establish the safety and recommended phase II dose (RP2D) of umbilical cord blood (CB)- derived natural killer (NK) cells transduced with ONC-PluReceptor (CD3 complex/IL-15) in combination with epcoritamab and tafasitamab for patients with relapsed/refractory (R/R) CD19/CD20-positive B-cell non-Hodgkin lymphomas.

Secondary Objectives:

  1. To evaluate the overall response rate (ORR), complete response (CR) rate and partial response (PR) rate of patients treated at the RP2D.
  2. To evaluate the duration of response (DOR).
  3. To evaluate the progression-free survival (PFS) rate.
  4. To evaluate the overall survival (OS) time.
  5. To quantify the persistence of infused donor NK cells in the recipient.
  6. To conduct comprehensive immune reconstitution studies.

研究类型

介入性

注册 (估计的)

30

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • The University of Texas M. D. Anderson Cancer Center
        • 接触:
        • 首席研究员:
          • Yago Nieto, MD,PHD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients with R/R DLBCL or FL with all of the following:

    Failure of >/= 2 prior lines of therapy, or an autologous or allogeneic stem cell transplant.

    Prior failure of CAR-T or not eligible for CAR-T cells.

  2. Tumor biopsy positive for CD19 or CD20 at >/= 1% by immunohistochemistry or flow cytometry.

  3. Age 18-80 years.

  4. Karnofsky performance status >/=60%.

  5. Absolute neutrophil count >/=500/mm3 and platelet count >/=50,000/mm3.

  6. Serum creatinine clearance (CrCl) >/=30 ml/min, estimated using the Cockcroft-Gault equation:

    Estimated creatinine clearance = (140-age [years]) x weight (kg) (x Fa) / serum creatinine (mg/dL) x 72 [a where F=0.85 for females and F=1 for males].

  7. Adequate hepatic function (ALT and/or AST </=3 x upper limit of normal (ULN); bilirubin and ALP </=2 x ULN). Patients with cancer involvement of the liver and elevation of ALT, AST, bilirubin, and/or ALP </= 5 x ULN are eligible, per PI discretion.

  8. Adequate pulmonary function with FEV1, FVC and DLCO (corrected for hemoglobin and volume) >/=50%.

  9. Adequate cardiac function with left ventricular ejection fraction >/=40%, and no uncontrolled arrhythmias or symptomatic cardiac disease.

  10. If female of child-bearing potential, she must not be pregnant or breastfeeding and required to have a negative urine or serum pregnancy test prior to enrollment.

  11. Female participants of non-childbearing potential must meet at least one of the following criteria:

    i. Postmenopausal (no menses in greater than or equal to 12 consecutive months).

    ii. History of hysterectomy or bilateral salpingo-oophorectomy. iii. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).

    o Subjects who are of childbearing potential, sexually active, and at risk of pregnancy must agree to use a highly effective method of contraception for the duration of the active treatment and at least 3 months post-completion of the study therapy. See Appendix B. Highly effective methods of contraception include the following:

    iv. Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

    o Men treated or enrolled in this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study agent administration. Men who are able to have children must use effective birth control while in the study. If the male participant fathers a child or suspects that he has fathered a child while in the study, he must immediately notify his doctor.

  12. Agree to sign the consent to the long-term follow-up protocol PA17-0843 to fulfill the institutional responsibilities to various regulatory agencies

Exclusion Criteria:

  1. Lymphoma in CR with no measurable sites of disease.
  2. Major surgery <4 weeks prior to first dose of study drug.
  3. Any other severe or uncontrolled disease or condition that might increase the risk associated with study participation.
  4. Any other malignancy known to be active, with the exception of treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.
  5. Grade >/= 3 non-hematologic toxicity from prior therapy that has not improved to grade </= 2.
  6. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA.>/=10,000 copies/mL, or >/=2,000 IU/mL), or hepatitis C (detectable viral load by HCV RNA PCR)
  7. Active infection requiring parenteral antibiotics.
  8. HIV infection.
  9. Treatment within prior 2 weeks with any anti-cancer agent, investigational or approved.
  10. Active central nervous system (CNS) involvement (untreated parenchymal brain metastasis or positive cytology of cerebrospinal fluid).
  11. Life expectancy </= 6 months.
  12. Active and uncontrolled neurological disorder.
  13. Patients receiving systemic steroid therapy at the time of enrollment (physiological substitutive doses are allowed), or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment.
  14. Patients receiving immunosuppressive therapy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:第2周期:ONC-PluReceptor NK细胞剂量递增/剂量扩展治疗

Given by injection

实验性的:ESC/EXP1_周期 1: 剂量递增/ 使用 ONC-PluReceptor NK 细胞的剂量扩展治疗

Given by injection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and Adverse Events (AEs)
大体时间:Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Through study completion; an average of 1 year.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Yago Nieto, MD,PHD、M.D. Anderson Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月24日

初级完成 (估计的)

2031年9月30日

研究完成 (估计的)

2033年9月30日

研究注册日期

首次提交

2025年12月11日

首先提交符合 QC 标准的

2025年12月11日

首次发布 (实际的)

2025年12月16日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月31日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2024-0257
  • NCI-2025-09213 (其他标识符:NCI-CTRP Clinical Trials Registry)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅